Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
3H (Suzhou) Pharmaceuticals Co. Ltd. manages a company patent portfolio in the Biotechnology and Pharmaceuticals technology area. The portfolio currently has 1 pending office action, which is being reviewed by 1 distinct examiner. This single action is situated within 1 distinct art unit, indicating a highly focused and concentrated prosecution environment for the company's current filings.
The busiest examiner for this portfolio is SEITZ, ANTHONY JOSEPH, who is currently handling 1 pending office action. Because the busiest examiner pending count is 1, this individual is responsible for the entirety of the portfolio's active prosecution. For a practitioner, this means that the outcome of the current matter depends entirely on the specific requirements and tendencies of SEITZ, ANTHONY JOSEPH.
The presence of 1 distinct art unit and 1 distinct examiner suggests a straightforward prosecution path without the need to coordinate across different administrative groups. Strategy should be tailored specifically to the standards of the identified art unit. Successfully resolving the 1 pending office action will require a clear understanding of the examiner's perspective on the company's technology.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEITZ, ANTHONY JOSEPH | 1 | 67.8% | +27.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18693543 | FGFR INHIBITORS AND METHODS OF USE THEREOF | SEITZ, ANTHONY JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18693543 | FGFR INHIBITORS AND METHODS OF USE THEREOF | SEITZ, ANTHONY JOSEPH | 1629 | §103 | Non-Final OA | — | Pending | Mar 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial3H (Suzhou) Pharmaceuticals Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Anthony Joseph Seitz has the most, with 1 of 3H (Suzhou) Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
